LOBBYIST

Daniel Todd

175ACTIVITIES

8ORGS REPRESENTED

5BILLS

Revolving door — covered positions

Federal positions Daniel held before / during the 2-year LDA window. This is the credibility signal — who they were inside the building before they started lobbying it.

Senior Health Counsel, Senate Finance Committee

Special Assistant, Office of Admin. Ct. - Medicare & Medicaid

Organizations represented

Orgs whose LD-2 filings list Daniel as an active lobbyist, sorted by activity volume.

Todd Strategy Group84 activities American Medical Association28 activities Pharmaceutical Research and Manufacturers of America (PhRMA)22 activities Bristol Myers Squibb12 activities Eli Lilly and Company12 activities U.s. Chamber of Commerce Global Innovation Policy Center9 activities Coalition for the 21St Century5 activities U.S. Chamber of Commerce3 activities

Bills they file on

S. 86415 mentions

H.R. 16728 mentions

H.R. 9468 mentions

H.R. 52694 mentions

H.R. 14064 mentions

Topics in Filings

Policy topics Daniel files on across all their LD-2 activities.

Medicare and Medicaid Issues×22

HELP Copays Act×15

Physician Payment Reform×14

Intellectual property protection×12

Prescription Drug Pricing Policy×12

Part D changes×11

Prescription drug payment reform. 340B issues×11

General Medicare and Medicaid Issues×11

Drug Pricing and Access×11

Pharmaceutical Supply Chain×11

Pharmacy Benefit Managers×11

Show all 59 topics (+47 more) ▾

Medicare/Medicaid payment reform×10

Supply Chain Issues×10

Alzheimer's Disease×10

Medicare Contractor Reform×9

Maintaining Investments in New Innovation Act×8

ORPHAN Cures Act×8

Biosimilars reimbursement issues×6

Pharmacy Benefit Manager Reform×6

Anti Obesity Medication×6

Medicare/Medicaid Coverage and Reimbursement×6

PDUFA. 340B Program×6

Medicare coverage and reimbursement for diagnostics×5

FDA LDT Regulation×5

Prior Authorization for Medicare Advantage×5

Prescription drug pricing, including MDRP×4

Substance Use Disorder Policy×4

Medicaid drug rebate program×4

Medicare Physician Fee Schedule Provider Reimbursement×4

PAMA AUC×4

Value of imaging×4

General Education on Apollo Global Management×4

Insurance regulation×4

Prescription drug pricing×4

Prostate cancer screening×4

Women's health×4

340B Program×4

Home Infusion for Part B Products×4

Medicare Reimbursement for New Technologies×4

Pediatric Priority Review Voucher Program×4

General issues×4

Diagnostics for patients with rare disease×4

Multi-Cancer Early Detection×4

Drug pricing×4

Medicare reimbursement for diagnostics×4

Lab test regulatory and reimbursement reform×4

Medicare Reimbursement for Prescription Drugs×4

Screening and Diagnosis×4

PET scan coverage and reimbursement and dementia care. 340B Program×4

PPRV×4

Medicare coverage of molecular testing for solid organ allograft rejection×4

Medicare payment of clinical laboratory tests×4

Prior authorization of molecular tests×4

Education around innovative testing for early detection of lung cancer and draft×4

Lung Cancer Screening and Prevention Act×4

Oncology/Artificial Intelligence×4

Hepatitis C Funding×4

March-in rights×1

Issue mix

LDA general-issue codes weighted by activity count.

Medicare/Medicaid70

Health Issues62

Pharmacy15

Taxation/Internal Revenue Code8

Economics/Economic Development4

Financial Institutions/Investments/Securities4